Imprimis Pharma (IMMY) Reports Q2 Loss of $0.35/Share

Imprimis Pharma (NASDAQ: IMMY) reported Q2 EPS of ($0.35), versus ($0.39) reported last year. Revenue for the quarter came in at $4.9 million, versus $1.97 million reported last year.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Reading (RDI) Tops Q2 EPS by 4c